From 2024 to 2028, the forecasted average length of stay for malignant neoplasm of the prostate in Canada shows a consistent decrease from 4.3 days in 2024 to 3.9 days in 2028. In 2023, the average length of stay was 4.4 days, marking a percentage decline each year: a 2.27% drop from 2023 to 2024, and further declines of approximately 2.33% annually through 2028. The compound annual growth rate (CAGR) over these five years indicates a decrease of about 2.38% per year.
Future trends to watch for:
- Advancements in minimally invasive surgical techniques and targeted therapies that could further reduce hospital stays.
- Potential changes in healthcare policy or funding impacting treatment protocols and lengths of stay.
